Syndax Pharmaceuticals Stock Cash Flow From Operations
| 1T3 Stock | EUR 12.80 0.10 0.78% |
Syndax Pharmaceuticals fundamentals help investors to digest information that contributes to Syndax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syndax Stock. The fundamental analysis module provides a way to measure Syndax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syndax Pharmaceuticals stock.
Syndax |
Syndax Pharmaceuticals Company Cash Flow From Operations Analysis
Syndax Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Syndax Pharmaceuticals Cash Flow From Operations | 29.13 M |
Most of Syndax Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syndax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Syndax Pharmaceuticals has 29.13 M in Cash Flow From Operations. This is 94.48% lower than that of the Healthcare sector and 53.41% lower than that of the Biotechnology industry. The cash flow from operations for all Germany stocks is 97.0% higher than that of the company.
Syndax Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syndax Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics of similar companies.Syndax Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Syndax Fundamentals
| Return On Equity | -0.0519 | |||
| Return On Asset | -0.0292 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 979.72 M | |||
| Shares Outstanding | 68.1 M | |||
| Shares Owned By Insiders | 4.22 % | |||
| Shares Owned By Institutions | 95.78 % | |||
| Price To Book | 4.08 X | |||
| Price To Sales | 12.70 X | |||
| Revenue | 139.71 M | |||
| Gross Profit | 139.71 M | |||
| EBITDA | 26.22 M | |||
| Net Income | 24.93 M | |||
| Cash And Equivalents | 95.37 M | |||
| Cash Per Share | 3.52 X | |||
| Total Debt | 19.89 M | |||
| Debt To Equity | 1.90 % | |||
| Current Ratio | 6.24 X | |||
| Book Value Per Share | 5.62 X | |||
| Cash Flow From Operations | 29.13 M | |||
| Target Price | 27.67 | |||
| Number Of Employees | 59 | |||
| Beta | 1.06 | |||
| Market Capitalization | 1.67 B | |||
| Total Asset | 449.66 M | |||
| Z Score | 49.8 | |||
| Net Asset | 449.66 M |
About Syndax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.